US launches Section 301 probe into Germany's pharma pricing policies
The United States has opened a trade investigation into Germany's pharmaceutical pricing policies, raising the prospect of new tariffs on a major European economy. The move was announced on Thursday and is being carried out under Section 301 of the Trade Act of 1974. It focuses on whether Germany's pricing practices for innovative medicines unfairly burden US commerce.According to the US Trade Representative's office, the probe will examine whether Germany's approach amounts to persistent underpayment for innovative pharmaceutical products that is unreasonable or discriminatory. The notice said evidence indicates Germany uses unfair pricing policies and practices in relation to innovative... [Continue Reading]
360LiveNews | 19 Jun 2026 04:33 LONDON
Sponsored
